David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board of directors, other execs join Merck, Apeiron Biologics, Vectura, Roivant, OncoSec, Breath Therapeutics, Immusoft and M3 Biotechnology.

This week's roundup includes some movement in big pharma with the appointment of a chief financial officer by Shire, a chief digital officer by Novartis and BenevolentAI hiring GSK's head of a discovery performance unit.

Struggling to restore investor confidence amid controversy, Akari has convinced former Zealand CEO David Solomon to take on the same role there and try to re-energize the NY-based biotech.

Hepatitis C is effectively cured. Could this success be replicated in another serious chronic viral condition ‒ HIV? Abivax, which last year abandoned its hepatitis B lead program, has bounced back with data suggesting a 'functional cure' for HIV is more than just a pipe dream.